| Prev Close | 1.92 |
| Open | 1.94 |
| Day Low/High | 1.90 / 2.04 |
| 52 Wk Low/High | 0.24 / 0.65 |
| Volume | 95.91K |
| Avg Volume | 240.60K |
| Exchange | AMEX |
| Shares Outstanding | 28.46M |
| Market Cap | 56.35M |
| EPS | -0.40 |
| Div & Yield | N.A. (N.A) |
Latest News
Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-3117
Patent Protection for RX-3117 Extended until 2036
Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective
Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial And Operational Results
Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences
Rexahn Pharmaceuticals Strengthens Leadership Team
Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer
Rexahn Pharmaceuticals Presents Clinical Data For Three Novel Targeted Oncology Programs At The 2016 American Society Of Clinical Oncology Annual Meeting
Data Show RX-3117, Archexin® and Supinoxin™ Appear to be Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Show Early Evidence of Clinical Activity
Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
Phase Ib Clinical Trial Successfully Completed and Maximum Tolerated Dose Determined
